Aarti Drugs invests ₹600 crore in capacity expansion
pre-market1 source ↓machine-written, see hownot a recommendation
- towards enhancing manufacturing
- ₹600 crore
- Currently trading
- ₹415
- and a P/E
- ₹3,788 crore
- P/E ratio
- 20x
- is operating
- 65% utilization
Aarti Drugs has committed ₹600 crore towards enhancing manufacturing capacity and backward integration. This investment aims to improve margins through reduced input costs and increased asset utilization. Currently trading at ₹415, the stock has a market cap of ₹3,788 crore and a P/E ratio of 20x. 📈
The Sayakha facility, crucial for producing key intermediates, is operating at 65% utilization. This expansion could significantly impact revenue and profitability for Aarti Drugs in the coming quarters.
Not investment advice. For informational purposes only.